EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity

Melanie Girard, Tianning Yu, Nathalia V Batista, Karen K M Yeung, Sara Lamorte, Wenting Gao, Miaoxi Liu, Tracy L McGaha, Tania H Watts iD

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkaf131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Melanie Girard und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Monocytes, Interferon Type I, Membrane Proteins, Melanoma, Experimental. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canadian Institutes of Health Research Canada, NHLBI NIH HHS, University of Toronto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, a sensor of cytosolic DNA, orchestrates the production of proinflammatory cytokines, chemokines, and type I interferons (IFN-Is), thereby contributing to spontaneous tumor surveillance. Intratumoral delivery of synthetic STING agonists induces IFN-I–dependent tumor regression in preclinical cancer models and is being tested clinically. In this study, we investigate the role of monocytic lineage cells (MCs) in response to STING agonist induced IFN-I signaling. We show that CCR2-deficient mice, lacking inflammatory MCs in the periphery, or Lyz2-Cre-IFNAR1fl/fl mice in which IFN-I signaling in monocytes is reduced, exhibit impaired responses to STING agonist therapy of MC38 and/or B16F10 tumors. STING agonist treatment induced CCR5-dependent migration of MCs carrying tumor antigen from the tumor to the lymph nodes. Single-cell RNA sequencing of CD45+ cells from lymph nodes and tumors of mice in which half the hematopoietic cells lack the IFNAR1 (interferon alpha/beta receptor 1) revealed that STING agonist therapy induces intrinsic IFNAR1-dependent acquisition of an inflammatory monocytic cell phenotype distinct from inflammatory classical dendritic cells (cDC) and a reduction in macrophages with a protumor TGFβ/angiogenesis transcriptome. Interleukin (IL)-18–IL-18R1 interaction was the top predicted interaction between monocytic lineage cells and CD8+ T cells or natural killer cells. Blocking IL-18 reduced IFN-γ production by CD8 T cells in lymph nodes and decreased the therapeutic efficacy of STING agonist treatment in Ccr2+/+ but not in Ccr2−/− mice. These findings support a pivotal role for IL-18 producing inflammatory monocytic lineage cells in CD8+ T cell control of melanoma following STING agonist treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MonocytesInterferon Type IMembrane ProteinsMelanoma, ExperimentalAnimalsMiceMice, Inbred C57BLMice, KnockoutSignal TransductionReceptor, Interferon alpha-betaCell LineageReceptors, CCR2Cell Line, TumorSTING Protein

Stichwörter der Autor:innen

IL-18STINGType I interferonmelanomamonocyte-derived cells

Substanzen

Interferon Type IMembrane ProteinsReceptor, Interferon alpha-betaReceptors, CCR2Sting1 protein, mouseSTING ProteinCcr2 protein, mouseIfnar1 protein, mouse

Autor:innen und Institutionen

  • Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Tumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

ORCID-Profile: Tania H Watts

Förderung

  • Canadian Institutes of Health Research Canada
  • NHLBI NIH HHS
  • University of Toronto
  • NIAID NIH HHS
  • CIHR
  • NIDA NIH HHS
  • Canadian Cancer Society
  • NIH HHS

Zitieren

APA

Girard, M., Yu, T., Batista, N. V., Yeung, K. K. M., Lamorte, S., Gao, W., Liu, M., McGaha, T. L., & Watts, T. H. (2025). STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf131

Vancouver

Girard M, Yu T, Batista NV, Yeung KKM, Lamorte S, Gao W, et al. STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf131

BibTeX
@article{Girard2025,
  author = {Girard, Melanie and Yu, Tianning and Batista, Nathalia V and Yeung, Karen K M and Lamorte, Sara and Gao, Wenting and Liu, Miaoxi and McGaha, Tracy L and Watts, Tania H},
  title = {STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkaf131}
}
Kostenlos starten →